Enhancing mTOR-targeted cancer therapy
Enhancing mTOR-targeted cancer therapy
批准号:
8107261
负责人:
Shi-Yong Sun
金额:
$26.71万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-08-15 至 2016-07-31
关键词:
26S proteasomeAlkylphosphocholine CompoundApoptosisBiological AssayBiologyCell Proliferation RegulationCell SurvivalCell physiologyCellsClinical TreatmentClinical TrialsComplexCoupledDiseaseFBXW7 geneGenesHomeostasisImmunoprecipitationKnock-outKnowledgeLearningMalignant NeoplasmsMediatingMolecularMutationPerifosinePharmaceutical PreparationsPhosphorylationPhosphorylation SitePlayProcessProteinsRaptorsRegimenRegulationReportingRoleSignal TransductionSirolimusSystemTestingTherapeuticUbiquitinUbiquitinationWestern BlottingWorkanalogcancer therapyhuman FRAP1 proteininhibitor/antagonistkinase inhibitormTOR proteinmulticatalytic endopeptidase complexnoveloverexpressionprotein degradationsmall moleculeubiquitin ligaseubiquitin-protein ligase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Ubiquitin proteasome-mediated protein degradation is an important process in maintaining cellular homeostasis through regulation of many important cellular processes, including differentiation, proliferation and apoptosis. Accordingly, aberrant protein degradation through this system underlies many diseases, including cancer. The mammalian target of rapamycin (mTOR), coupled with raptor and rictor to form mTOR complex 1 (mTORC1) and mTORC complex 2 (mTORC2), respectively, plays a critical role in the regulation of cell proliferation and survival. Hence, mTOR inhibitors including the conventional rapamycin and its analogues (rapalogs) and novel mTOR kinase inhibitors are either approved drugs for cancer therapy or being widely tested in clinical trials. We and other have suggested that mTOR, raptor and rictor can be degraded through a mechanism involving the E3 ubiquitin ligase FBXW7 (also called FBW7 or CDC4). However, the mechanisms underlying their degradation and the impact of degradation-mediated regulation of the mTOR axis on mTOR- targeted cancer therapy are largely unknown. In this proposal, we hypothesize that the key components in the mTOR complexes, rictor and raptor, are subjected to FBXW7-mediated and GSK3-dependent degradation. As a result, both mTORC1 and mTORC2 are regulated by the degradation mechanism. This hypothesis will be tested by accomplishing 3 aims: 1) to demonstrate FBXW7-mediated ubiquitination and proteasome degradation of raptor and rictor and its impact on the mTOR signaling; 2) to determine the involvement of GSK3 in FBXW7-mediated degradation of rictor and raptor; and 3) to evaluate the impact of degradation regulation of the mTOR axis on mTOR-targeted cancer therapy. The objectives of this proposal are to understand the mechanisms through which raptor and rictor are degraded and to determine the impact of regulation of the degradation of these proteins on mTOR-targeted cancer therapy.
PUBLIC HEALTH RELEVANCE: The objectives of the proposal are to understand the mechanisms through which raptor and rictor are degraded and to determine the impact of regulation of the degradation of these proteins on mTOR-targeted cancer therapy. Thus, this proposal not only helps us to understand the biology of mTOR regulation by degradation, but also has great translational significance that immediately impacts clinical treatment of cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
c-Myc modulation and its implications in EGFR-targeted cancer therapy
-
批准号:10427217
-
项目类别:
-
资助金额:$17.64万
-
财政年份:2020
-
负责人:Shi-Yong Sun
-
依托单位:
c-Myc modulation and its implications in EGFR-targeted cancer therapy
-
批准号:10212350
-
项目类别:
-
资助金额:$40.31万
-
财政年份:2020
-
负责人:Shi-Yong Sun
-
依托单位:
c-Myc modulation and its implications in EGFR-targeted cancer therapy
-
批准号:10649650
-
项目类别:
-
资助金额:$39.09万
-
财政年份:2020
-
负责人:Shi-Yong Sun
-
依托单位:
Modulation of death receptor 4 in EGFR-targeted cancer therapy
-
批准号:10006518
-
项目类别:
-
资助金额:$43.91万
-
财政年份:2018
-
负责人:Shi-Yong Sun
-
依托单位:
Modulation of death receptor 4 in EGFR-targeted cancer therapy
-
批准号:10524101
-
项目类别:
-
资助金额:$11.3万
-
财政年份:2018
-
负责人:Shi-Yong Sun
-
依托单位:
Modulation of death receptor 4 in EGFR-targeted cancer therapy
-
批准号:10653881
-
项目类别:
-
资助金额:$42.27万
-
财政年份:2018
-
负责人:Shi-Yong Sun
-
依托单位:
Modulation of death receptor 4 in EGFR-targeted cancer therapy
-
批准号:10428557
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Shi-Yong Sun
-
依托单位:
Modulation of death receptor 4 in EGFR-targeted cancer therapy
-
批准号:10206047
-
项目类别:
-
资助金额:$43.91万
-
财政年份:2018
-
负责人:Shi-Yong Sun
-
依托单位:
Therapeutic potential of mTOR kinase inhibitors in lung cancer
-
批准号:8624748
-
项目类别:
-
资助金额:$15.47万
-
财政年份:2012
-
负责人:Shi-Yong Sun
-
依托单位:
Therapeutic potential of mTOR kinase inhibitors in lung cancer
-
批准号:8639500
-
项目类别:
-
资助金额:$31.2万
-
财政年份:2012
-
负责人:Shi-Yong Sun
-
依托单位:
Therapeutic potential of mTOR kinase inhibitors in lung cancer
-
批准号:8825457
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2012
-
负责人:Shi-Yong Sun
-
依托单位:
Therapeutic potential of mTOR kinase inhibitors in lung cancer
-
批准号:8547856
-
项目类别:
-
资助金额:$16.45万
-
财政年份:2012
-
负责人:Shi-Yong Sun
-
依托单位:
Therapeutic potential of mTOR kinase inhibitors in lung cancer
-
批准号:8446302
-
项目类别:
-
资助金额:$30.23万
-
财政年份:2012
-
负责人:Shi-Yong Sun
-
依托单位:
TARGETING DEATH RECEPTOR-MEDIATED APOPTOSIS FOR HEAD AND NECK CANCER
-
批准号:7300625
-
项目类别:
-
资助金额:$33.1万
-
财政年份:2007
-
负责人:Shi-Yong Sun
-
依托单位:
Enhancing the mTOR-targeted cancer therapy
-
批准号:7646246
-
项目类别:
-
资助金额:$26.37万
-
财政年份:2006
-
负责人:Shi-Yong Sun
-
依托单位:
Enhancing the mTOR-targeted cancer therapy
-
批准号:7142018
-
项目类别:
-
资助金额:$27.16万
-
财政年份:2006
-
负责人:Shi-Yong Sun
-
依托单位:
Enhancing the mTOR-targeted cancer therapy
-
批准号:7269948
-
项目类别:
-
资助金额:$26.37万
-
财政年份:2006
-
负责人:Shi-Yong Sun
-
依托单位:
Enhancing mTOR-targeted cancer therapy
-
批准号:8890792
-
项目类别:
-
资助金额:$26.71万
-
财政年份:2006
-
负责人:Shi-Yong Sun
-
依托单位:
Enhancing mTOR-targeted cancer therapy
-
批准号:8699154
-
项目类别:
-
资助金额:$25.91万
-
财政年份:2006
-
负责人:Shi-Yong Sun
-
依托单位:
Enhancing the mTOR-targeted cancer therapy
-
批准号:7478812
-
项目类别:
-
资助金额:$26.37万
-
财政年份:2006
-
负责人:Shi-Yong Sun
-
依托单位: